Volume 7, Issue 2 (12-2020)                   vacres 2020, 7(2): 74-79 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Nazari M, Badmasti F. In Silico Evaluation of a Mutant Toxic Shock Syndrome Toxin-1 (TSST-1) of Staphylococcus aureus as a Putative Vaccine Candidate. vacres 2020; 7 (2) :74-79
URL: http://vacres.pasteur.ac.ir/article-1-242-en.html
Department of Bacteriology, Pasteur Institute of Iran, Tehran, Iran
Abstract:   (1901 Views)
Introduction: The development of a vaccine against Staphylococcus aureus has proven to be much more difficult than expected. In this study, we considered and analyzed a mutant Toxic Shock Syndrome Toxin-1 (TSST-1) as a potential vaccine candidate. Methods: An NCBI sequence of TSST-1 was analyzed bioinformatically by online tools such as Ensemble and Pubmlst. The protein sequence of TSST-1 was similarly analysed by Expasy ProtParam, Phyre2 and Vaxign databases. The protein functional class was predicted by VICMpred database while the B- and T-cell epitopes were predicted by IEDB and BepiPred tools. The 3D structure was predicted by LOMETS, QMEAN, ProSA-web and ElliPro. The conservation of the epitopes was evaluated by ConSurf tool.  Results: In silico analyses showed that this protein is present in high-prevalence sequence types of circulating clinical strains. It appears that TSST-1 has conserved liner and conformational B-cell epitopes. In addition, there are four potent of T-cell epitopes in this protein. Conclusion: This in silico data indicated that TSST-1 (and especially amino acid residues 81-221) is a promising vaccine target against S. aureus.
Full-Text [PDF 682 kb]   (851 Downloads)    
Type of Study: Research | Subject: Infectious diseases
Received: 2021/04/25

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 All Rights Reserved | Vaccine Research

Designed & Developed by : Yektaweb

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.